Gilead Sciences specializes in antiviral therapies, particularly in HIV, hepatitis, and, more recently, COVID-19. Its differentiators include breakthrough treatments that have transformed standards of care in infectious diseases. Gilead Canada, headquartered in Mississauga, focuses on medical, regulatory, and commercial activities supporting access to its medicines nationwide. The Canadian team partners with clinical researchers and public health stakeholders to advance treatment outcomes. Gilead also maintains a commitment to community programs addressing health equity.